Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | BMP1 | P13497 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5189511 | 0.82 | ESR1 (0.80) | ESR1NR1I2L3MBTL1TSHRMAPK1 | |
| SCHEMBL10312363 | 0.82 | MAPK1 (0.50) | ESR1MAPK1KMT2ABMP1LMNA | |
| SCHEMBL10312362 | 0.81 | TDP1 (0.47) | ESR1NR1I2MAPK1LMNAHSD11B1 | |
| SCHEMBL10438567 | 0.78 | ESR1 (0.79) | ESR1NR1I2L3MBTL1TSHRMAPK1 | |
| SCHEMBL10312366 | 0.77 | KMT2A (0.43) | ESR1KMT2ALMNA | |
| SCHEMBL15677252 | 0.76 | CNR2 (0.56) | KMT2ABMP1 | |
| SCHEMBL16015202 | 0.75 | ESR1 (0.53) | ESR1NR1I2L3MBTL1RORCTSHR | |
| SCHEMBL6428043 | 0.74 | ESR1 (0.77) | ESR1NR1I2RORCTSHRMAPK1 | |
| SCHEMBL8466425 | 0.74 | ESR1 (0.76) | ESR1NR1I2L3MBTL1TSHRMAPK1 | |
| SCHEMBL5740587 | 0.73 | NR1I2 (0.69) | ESR1NR1I2L3MBTL1RORCTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828879-B2 | Silicon-containing composition having sulfonamide group for forming resist underlayer film | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20120178261-A1 | SILICON-CONTAINING COMPOSITION HAVING SULFONAMIDE GROUP FOR FORMING RESIST UNDERLAYER FILM | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178261-A1 | SILICON-CONTAINING COMPOSITION HAVING SULFONAMIDE GROUP FOR FORMING RESIST UNDERLAYER FILM | STS, SI, MUS81 | ESR1 2543/4885NR1I2 3866/4885L3MBTL1 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.